Tesarakt

Reinventing Brain Care Through AI

Tesarakt operates in computational bio based in United States, founded in 2022.

Profile

Neurological disorders, like Alzheimer’s, can be challenging to diagnose, especially earlier in the disease progression when symptoms are subtle. Based on the groundbreaking research carried out in Scott Small’s lab at Columbia University, Tesarakt uses AI and machine learning to enhance the predictive power of neurodiagnosis using conventional MRI scans, and powered with access to the largest database of MRI scans. Parkinson’s disease & Alzheimer’s disease are the initial indications they are pursuing, with the potential to detect both diseases years before first symptoms arise.

The company sits in the computational bio segment, where it competes on its core product or service.

The business is associated with United States.

It is recorded at the SOSV portfolio company stage.

The company reports a headcount in the 2-10 range.

Website: www.tesarakt.com